{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:04:08Z","timestamp":1787868248467,"version":"build-2784847793"},"reference-count":38,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,1,31]],"date-time":"2006-01-31T00:00:00Z","timestamp":1138665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2006,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Twenty previously synthesized fused heterocyclic DNA\u2010topoisomerase II (Topo II)\u2010inhibiting compounds were investigated for their potential efficacy in various human cancer cell lines that were derived from different tumor entities. Moreover, different multidrug\u2010resistant variants of these cancer cell lines with decreased Topo II expression were investigated. In parental, drug\u2010sensitive cells merely the compounds BD3 and G35 showed efficacies, in terms of \u03bcM, which were similar to that of the classical Topo II inhibitor etoposide. On the other hand, most of the tested heterocyclic compounds were found more effective in drug\u2010resistant cells than in the parental, drug\u2010sensitive ones, and some of the compounds showed high antineoplastic efficacy in several drug\u2010resistant cell models. Compounds BD13, BD14 and BD16 exhibited high antineoplastic activities against the drug\u2010resistant sublines EPG85\u2010257RNOV and EPG85\u2010257RDB derived from gastric carcinoma, EPP85\u2010181RNOV and EPP85\u2010181RDB derived from pancreatic carcinoma, MCF\u20107\/Adr derived from breast cancer, D79\/86RNOV derived from fibrosarcoma, and MeWoETO1 derived from melanoma. Furthermore, compound D23 was found highly efficient in the multidrug\u2010resistant variants HT\u201029RNOV and HT\u201029RDB derived from colon carcinoma, and compound D24 exhibited the highest antineoplastic activity among the tested compounds in the drug\u2010resistant subline MDA\u2010MB\u2010231ROV derived from breast cancer. In conclusion, compounds BD 13, BD 14, BD 16, D 23 and D 24 may be useful for the treatment of different multidrug\u2010resistant cancer cells with cross resistance against \u201cclassical\u201d Topo II\u2010targeting drugs. \u00a9 2006 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ijc.21792","type":"journal-article","created":{"date-parts":[[2006,1,31]],"date-time":"2006-01-31T21:47:14Z","timestamp":1138744034000},"page":"213-220","source":"Crossref","is-referenced-by-count":44,"title":["High antineoplastic activity of new heterocyclic compounds in cancer cells with resistance against classical DNA topoisomerase II\u2010targeting drugs"],"prefix":"10.1002","volume":"119","author":[{"given":"Hermann","family":"Lage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esin","family":"Aki\u2010Sener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Yalcin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,4,17]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(02)00715-5"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0921-4410(03)21005-X"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/20.21.5587"},{"key":"e_1_2_5_5_2","first-page":"209","article-title":"Proliferation\u2010 and cell cycle\u2010dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH\u20103T3 cells","volume":"2","author":"Woessner RD","year":"1991","journal-title":"Cell Growth Differ"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4781(98)00132-8"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568026033452519"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.81.5.1361"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1042\/BST0290702"},{"key":"e_1_2_5_10_2","first-page":"3075","article-title":"Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors","volume":"46","author":"Pommier Y","year":"1986","journal-title":"Cancer Res"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00424a026"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.1999.0947"},{"key":"e_1_2_5_13_2","first-page":"4729","article-title":"Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine\u2010resistant form of topoisomerase II","volume":"51","author":"Hinds M","year":"1991","journal-title":"Cancer Res"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.03.093"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1054-3589(08)61134-5"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207237"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19970529)71:5<817::AID-IJC20>3.0.CO;2-3"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(01)02722-3"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1159\/000075356"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-002-0349-y"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)43815-4"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1522-2683(19991001)20:14<2961::AID-ELPS2961>3.0.CO;2-L"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.5.429"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.81.5.1361"},{"key":"e_1_2_5_25_2","first-page":"5141","article-title":"Isolation of amplified and overexpressed DNA sequences from adriamycin\u2010resistant human breast cancer cells","volume":"47","author":"Fairchild CR","year":"1987","journal-title":"Cancer Res"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/53.3.661"},{"key":"e_1_2_5_27_2","first-page":"215","volume-title":"The nude mouse in experimental and clinical research","author":"Fogh J","year":"1978"},{"key":"e_1_2_5_28_2","first-page":"4359","article-title":"Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto\u2010oncogene expression","volume":"17","author":"Kern MA","year":"1997","journal-title":"Anticancer Res"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(01)02304-3"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.97.5.695"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2005.17.2.215"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.11.016"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.200300851"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0308520101"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj0510070"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-827X(00)00070-7"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(03)00203-6"},{"key":"e_1_2_5_38_2","first-page":"1087","article-title":"Induction of apoptosis and necrosis by resistance modifiers benzazoles and benzoxazines on tumour cell line mouse lymphoma L5718 Mdr+cells","volume":"19","author":"Varga A","year":"2005","journal-title":"In Vivo"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050751"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.21792","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.21792","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T20:31:55Z","timestamp":1695933115000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.21792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,17]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["10.1002\/ijc.21792"],"URL":"https:\/\/doi.org\/10.1002\/ijc.21792","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,17]]}}}